• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Plasma sIL-2Rα levels are associated with disease progression in myelofibrosis with JAK2 but not CALR mutation.

作者信息

Barosi Giovanni, Campanelli Rita, Catarsi Paolo, De Amici Mara, Abbà Carlotta, Viarengo Gianluca, Villani Laura, Gale Robert P, Rosti Vittorio, Massa Margherita

机构信息

Center for the Study of Myelofibrosis, Laboratory of Biochemistry-Biotechnology and Advanced Diagnosis, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico S. Matteo, Pavia, Italy.

Center for the Study of Myelofibrosis, Laboratory of Biochemistry-Biotechnology and Advanced Diagnosis, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico S. Matteo, Pavia, Italy.

出版信息

Leuk Res. 2020 Mar;90:106319. doi: 10.1016/j.leukres.2020.106319. Epub 2020 Feb 11.

DOI:10.1016/j.leukres.2020.106319
PMID:32081398
Abstract
摘要

相似文献

1
Plasma sIL-2Rα levels are associated with disease progression in myelofibrosis with JAK2 but not CALR mutation.血浆可溶性白细胞介素-2受体α水平与伴有JAK2而非CALR突变的骨髓纤维化疾病进展相关。
Leuk Res. 2020 Mar;90:106319. doi: 10.1016/j.leukres.2020.106319. Epub 2020 Feb 11.
2
An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis.一种由年龄、JAK2、CALR和MPL突变状态组成的用于原发性骨髓纤维化患者的准确、简单的预后模型。
Haematologica. 2017 Jan;102(1):79-84. doi: 10.3324/haematol.2016.149765. Epub 2016 Sep 29.
3
Co-existence of JAK2 V617F and CALR mutations in primary myelofibrosis.原发性骨髓纤维化中JAK2 V617F和CALR突变的共存
Leuk Lymphoma. 2015;56(10):2973-4. doi: 10.3109/10428194.2015.1015124. Epub 2015 Mar 11.
4
Effect of CALR and JAK2 mutations on the clinical and hematological phenotypes of the disease in patients with myelofibrosis - long-term experience from a single center.CALR 和 JAK2 突变对骨髓纤维化患者疾病临床和血液学表型的影响——来自单一中心的长期经验。
Neoplasma. 2018;65(2):296-303. doi: 10.4149/neo_2018_170426N313.
5
The clinical and prognostic relevance of driver mutations in 203 Taiwanese patients with primary myelofibrosis.203 例台湾原发性骨髓纤维化患者中驱动基因突变的临床和预后相关性。
J Clin Pathol. 2018 Jun;71(6):514-521. doi: 10.1136/jclinpath-2017-204829. Epub 2017 Dec 4.
6
Clinical features of JAK2V617F- or CALR-mutated essential thrombocythemia and primary myelofibrosis.JAK2V617F或CALR突变的原发性血小板增多症和原发性骨髓纤维化的临床特征。
Blood Cells Mol Dis. 2016 Sep;60:74-7. doi: 10.1016/j.bcmd.2016.03.003. Epub 2016 Mar 8.
7
Frequency and molecular characteristics of calreticulin gene (CALR) mutations in patients with JAK2 -negative myeloproliferative neoplasms.JAK2阴性骨髓增殖性肿瘤患者中钙网蛋白基因（CALR）突变的频率及分子特征
Acta Haematol. 2015;133(2):193-8. doi: 10.1159/000366263. Epub 2014 Oct 16.
8
Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations.伴有CALR或JAK2突变的原发性血小板增多症的表型与预后分析。
Haematologica. 2015 Jul;100(7):893-7. doi: 10.3324/haematol.2014.118299. Epub 2015 May 1.
9
Improved Survival of Calreticulin-Mutated Patients Compared With Janus Kinase 2 in Primary Myelofibrosis: A Meta-Analysis.原发性骨髓纤维化中，与Janus激酶2相比，钙网蛋白突变患者的生存率提高：一项荟萃分析。
Clin Lymphoma Myeloma Leuk. 2016 May;16(5):264-8. doi: 10.1016/j.clml.2016.01.009. Epub 2016 Feb 6.
10
Incidence, clinical features, and prognostic impact of CALR exon 9 mutations in essential thrombocythemia and primary myelofibrosis: an experience of a single tertiary hospital in Korea.韩国一家三级医院的经验：真性红细胞增多症和原发性骨髓纤维化中CALR外显子9突变的发生率、临床特征及预后影响
Ann Lab Med. 2015 Mar;35(2):233-7. doi: 10.3343/alm.2015.35.2.233. Epub 2015 Feb 12.

引用本文的文献

1
Thrombosis in myeloproliferative neoplasms: a viewpoint on its impact on myelofibrosis, mortality, and solid tumors.骨髓增殖性肿瘤中的血栓形成：对其影响骨髓纤维化、死亡率和实体瘤的观点。
Blood Cancer J. 2024 Oct 25;14(1):188. doi: 10.1038/s41408-024-01169-6.
2
Functionally Relevant Cytokine/Receptor Axes in Myelofibrosis.骨髓纤维化中功能相关的细胞因子/受体轴
Biomedicines. 2023 Sep 5;11(9):2462. doi: 10.3390/biomedicines11092462.
3
Diabetes and Second Neoplasia Impact on Prognosis in Pre-Fibrotic Primary Myelofibrosis.糖尿病和第二原发性肿瘤对纤维化前原发性骨髓纤维化预后的影响。
Cancers (Basel). 2022 Apr 1;14(7):1799. doi: 10.3390/cancers14071799.
4
New Markers of Disease Progression in Myelofibrosis.骨髓纤维化疾病进展的新标志物
Cancers (Basel). 2021 Oct 23;13(21):5324. doi: 10.3390/cancers13215324.
5
Clinical Relevance of (rs3025039) +936 C>T Polymorphism in Primary Myelofibrosis: Susceptibility, Clinical Co-Variates, and Outcomes.原发性骨髓纤维化中 (rs3025039) +936 C>T 多态性的临床相关性：易感性、临床共变量和结局。
Genes (Basel). 2021 Aug 20;12(8):1271. doi: 10.3390/genes12081271.
6
Inflammatory Pathophysiology as a Contributor to Myeloproliferative Neoplasms.炎性发病机制作为骨髓增殖性肿瘤的一个致病因素。
Front Immunol. 2021 Jun 1;12:683401. doi: 10.3389/fimmu.2021.683401. eCollection 2021.
7
Cytokine Profiling in Myeloproliferative Neoplasms: Overview on Phenotype Correlation, Outcome Prediction, and Role of Genetic Variants.骨髓增殖性肿瘤中的细胞因子谱分析：表型相关性、预后预测及遗传变异的作用概述。
Cells. 2020 Sep 21;9(9):2136. doi: 10.3390/cells9092136.